Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Regeneron Pharmaceuticals (REGN) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareBiotechnologyREGN

Closing price · Nov 19, 2026 $932.53 -1.4% on the day · +33.4% over 12 months 52-week range $599.96 – $973.36
Get REGN alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling11last 12 months
Reported sales$65.2M136 of 174 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
Latest open-market trade

Sale George L. Sing, Director sold 1,000 shares at $960.26 ($960K).

Trade date
Nov 16, 2026
Disclosed to the SEC
Nov 18, 2026
Type
Sale (code S)

Read the original SEC filing ↗All REGN insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

REGN insider transactions (Form 4)

Open-market purchases and sales. 73 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 18SEC George L. SingDirector Sell 1,00024,147 held (−4%) $960.26 $960K -2.9% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 67150,434 held (−1%) $953.69 $640K -2.2% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 58447,669 held (−1%) $961.45 $561K -3.0% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 50648,510 held (−1%) $959.45 $485K -2.8% —
Nov 18SEC George L. SingDirector Sell 46523,147 held (−2%) $958.11 $446K -2.7% —
Nov 18SEC George L. SingDirector Sell 35923,612 held (−1%) $957.49 $344K -2.6% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 34649,462 held (−1%) $956.70 $331K -2.5% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 34046,779 held (−1%) $964.36 $328K -3.3% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 31349,808 held (−1%) $955.48 $299K -2.4% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 31350,121 held (−1%) $954.45 $299K -2.3% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 29547,374 held (−1%) $962.70 $284K -3.1% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 29851,325 held (−1%) $951.75 $284K -2.0% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 25748,253 held (−1%) $960.65 $247K -2.9% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 25547,119 held (−1%) $963.60 $246K -3.2% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 24449,016 held (−0%) $958.27 $234K -2.7% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 22051,105 held (−0%) $952.75 $210K -2.1% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 20249,260 held (−0%) $957.53 $193K -2.6% —
Nov 18SEC George L. SingDirector Sell 17623,971 held (−1%) $956.96 $168K -2.6% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 9351,697 held (−0%) $949.69 $88K -1.8% —
Nov 18SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 7451,623 held (−0%) $950.61 $70K -1.9% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 6610,606 held (−1%) $959.46 $63K -2.8% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 6310,331 held (−1%) $965.62 $61K -3.4% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 5910,498 held (−1%) $961.36 $57K -3.0% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 5910,768 held (−1%) $954.46 $56K -2.3% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 4910,557 held (−0%) $960.31 $47K -2.9% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 4410,672 held (−0%) $958.47 $42K -2.7% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 4410,827 held (−0%) $952.79 $42K -2.1% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 4210,415 held (−0%) $963.70 $40K -3.2% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 4110,457 held (−0%) $962.44 $39K -3.1% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 3010,738 held (−0%) $955.51 $29K -2.4% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 2610,305 held (−0%) $971.93 $25K -4.1% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 2210,716 held (−0%) $956.01 $21K -2.5% —
Nov 18SEC Marion McCourtEvp Commercial Sell Plan 2110,394 held (−0%) $964.69 $20K -3.3% —
Nov 6SEC Jason PitofskySvp Controller Sell 1,2154,944 held (−20%) $942.31 $1.1M -1.0% —
Nov 6SEC Jason PitofskySvp Controller Sell 9826,159 held (−14%) $941.58 $925K -1.0% —
Nov 6SEC Jason PitofskySvp Controller Sell 5757,141 held (−7%) $940.46 $541K -0.8% —
Nov 6SEC Jason PitofskySvp Controller Sell 5294,415 held (−11%) $943.53 $499K -1.2% —
Nov 6SEC Jason PitofskySvp Controller Sell 4397,716 held (−5%) $939.57 $412K -0.7% —
Nov 6SEC Jason PitofskySvp Controller Sell 179 $950.76 $170K -1.9% —
Nov 6SEC Jason PitofskySvp Controller Sell 1084,307 held (−2%) $944.22 $102K -1.2% —
Nov 6SEC Jason PitofskySvp Controller Sell 354,272 held (−1%) $945.61 $33K -1.4% —
Nov 5SEC Huda Y. ZoghbiDirector Sell 6,9392,203 held (−76%) $970.42 $6.7M -3.9% —
Nov 5SEC Huda Y. ZoghbiDirector Sell 5001,703 held (−23%) $971.06 $486K -4.0% —
Nov 4SEC George L. SingDirector Sell 7,07327,909 held (−20%) $965.38 $6.8M -3.4% —
Nov 4SEC George L. SingDirector Sell 4,33837,652 held (−10%) $963.47 $4.2M -3.2% —
Nov 4SEC Joseph J. LarosaGeneral Counsel Sell 3,93939,433 held (−9%) $965.41 $3.8M -3.4% —
Nov 4SEC Christine A. PoonDirector Sell 3,2036,357 held (−34%) $969.50 $3.1M -3.8% —
Nov 4SEC George L. SingDirector Sell 2,67034,982 held (−7%) $964.57 $2.6M -3.3% —
Nov 4SEC George L. SingDirector Sell 2,52241,990 held (−6%) $962.61 $2.4M -3.1% —
Nov 4SEC Christine A. PoonDirector Sell 2,4999,560 held (−21%) $968.58 $2.4M -3.7% —
Nov 4SEC George L. SingDirector Sell 1,52226,387 held (−5%) $966.27 $1.5M -3.5% —
Nov 4SEC George L. SingDirector Sell 1,22445,052 held (−3%) $960.57 $1.2M -2.9% —
Nov 4SEC George L. SingDirector Sell 1,04025,347 held (−4%) $967.07 $1.0M -3.6% —
Nov 4SEC Christine A. PoonDirector Sell 9375,420 held (−15%) $970.51 $909K -3.9% —
Nov 4SEC Christine A. PoonDirector Sell 77212,059 held (−6%) $967.38 $747K -3.6% —
Nov 4SEC George L. SingDirector Sell 54044,512 held (−1%) $961.85 $519K -3.0% —
Nov 4SEC Joseph J. LarosaGeneral Counsel Sell 52738,906 held (−1%) $966.11 $509K -3.5% —
Nov 4SEC Christine A. PoonDirector Sell 21812,831 held (−2%) $966.74 $211K -3.5% —
Nov 4SEC Christine A. PoonDirector Sell 2015,219 held (−4%) $971.31 $195K -4.0% —
Nov 4SEC George L. SingDirector Sell 20025,147 held (−1%) $970.18 $194K -3.9% —
Nov 3SEC Michael S. BrownDirector Sell Plan 1,9291,380 held (−58%) $875.00 $1.7M +6.6% —
Nov 3SEC Marion McCourtEvp Commercial Sell Plan 1,13210,871 held (−9%) $869.43 $984K +7.3% —
Nov 3SEC Kathryn GuariniDirector Sell Plan 400603 held (−40%) $900.00 $360K +3.6% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 46347,883 held (−1%) $780.63 $361K +19.5% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 45448,726 held (−1%) $778.64 $354K +19.8% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 38048,346 held (−1%) $779.59 $296K +19.6% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 37649,284 held (−1%) $775.46 $292K +20.3% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 28350,216 held (−1%) $771.56 $218K +20.9% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 27950,935 held (−1%) $766.47 $214K +21.7% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 27151,214 held (−1%) $765.39 $207K +21.8% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 22449,781 held (−0%) $773.40 $173K +20.6% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 21951,485 held (−0%) $764.40 $167K +22.0% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 21150,005 held (−0%) $772.56 $163K +20.7% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 19250,743 held (−0%) $767.39 $147K +21.5% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 12750,511 held (−0%) $769.30 $98K +21.2% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 12149,660 held (−0%) $774.48 $94K +20.4% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 10550,638 held (−0%) $768.33 $81K +21.4% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 7451,811 held (−0%) $760.65 $56K +22.6% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 6649,218 held (−0%) $776.31 $51K +20.1% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 5551,729 held (−0%) $762.57 $42K +22.3% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 5047,833 held (−0%) $781.47 $39K +19.3% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 3849,180 held (−0%) $777.76 $30K +19.9% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 3551,939 held (−0%) $755.91 $26K +23.4% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 2751,784 held (−0%) $761.36 $21K +22.5% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 2551,704 held (−0%) $763.76 $19K +22.1% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 2451,899 held (−0%) $758.16 $18K +23.0% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 1651,923 held (−0%) $757.68 $12K +23.1% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 1451,885 held (−0%) $759.96 $11K +22.7% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 1250,499 held (−0%) $770.20 $9K +21.1% —
Oct 15SEC Andrew J. MurphyCo-Chief Scientific Officer Sell Plan 651,974 held (−0%) $753.76 $5K +23.7% —
Sep 3SEC Marion McCourtEvp Commercial Sell Plan 1,21513,134 held (−8%) $850.00 $1.0M +9.7% —
Sep 3SEC Marion McCourtEvp Commercial Sell Plan 1,13112,003 held (−9%) $857.39 $970K +8.8% —
Sep 3SEC Kathryn GuariniDirector Sell Plan 400603 held (−40%) $850.00 $340K +9.7% —
Aug 12SEC Huda Y. ZoghbiDirector Sell Plan 8001,703 held (−32%) $800.00 $640K +16.6% —
Aug 12SEC Kathryn GuariniDirector Sell Plan 400603 held (−40%) $800.00 $320K +16.6% —
Jul 7SEC Arthur F. RyanDirector Sell Plan 20017,303 held (−1%) $650.15 $130K +43.4% —
May 4SEC Arthur F. RyanDirector Sell Plan 2417,559 held (−0%) $703.46 $17K +32.6% —
May 4SEC Arthur F. RyanDirector Sell Plan 1517,544 held (−0%) $704.28 $11K +32.4% —
May 4SEC Arthur F. RyanDirector Sell Plan 1517,583 held (−0%) $702.46 $11K +32.8% —
May 4SEC Arthur F. RyanDirector Sell Plan 1417,530 held (−0%) $705.56 $10K +32.2% —
May 4SEC Arthur F. RyanDirector Sell Plan 717,523 held (−0%) $706.74 $5K +31.9% —
May 4SEC Arthur F. RyanDirector Sell Plan 617,513 held (−0%) $709.45 $4K +31.4% —
May 4SEC Arthur F. RyanDirector Sell Plan 517,506 held (−0%) $711.49 $4K +31.1% —
May 4SEC Arthur F. RyanDirector Sell Plan 517,598 held (−0%) $701.76 $4K +32.9% —
May 4SEC Arthur F. RyanDirector Sell Plan 417,519 held (−0%) $707.40 $3K +31.8% —
May 4SEC Arthur F. RyanDirector Sell Plan 217,503 held (−0%) $714.13 $1K +30.6% —
May 4SEC Arthur F. RyanDirector Sell Plan 217,511 held (−0%) $710.87 $1K +31.2% —
May 4SEC Arthur F. RyanDirector Sell Plan 117,505 held (−0%) $712.09 $712 +31.0% —
Apr 3SEC Arthur F. RyanDirector Sell Plan 4017,603 held (−0%) $779.71 $31K +19.6% —
Apr 3SEC Arthur F. RyanDirector Sell Plan 1417,669 held (−0%) $775.58 $11K +20.2% —
Apr 3SEC Arthur F. RyanDirector Sell Plan 1317,656 held (−0%) $776.62 $10K +20.1% —
Apr 3SEC Arthur F. RyanDirector Sell Plan 917,647 held (−0%) $777.42 $7K +20.0% —
Apr 3SEC Arthur F. RyanDirector Sell Plan 817,683 held (−0%) $774.58 $6K +20.4% —
Apr 3SEC Arthur F. RyanDirector Sell Plan 817,691 held (−0%) $773.59 $6K +20.5% —
Apr 3SEC Arthur F. RyanDirector Sell Plan 417,643 held (−0%) $778.24 $3K +19.8% —
Apr 3SEC Arthur F. RyanDirector Sell Plan 317,699 held (−0%) $772.76 $2K +20.7% —
Apr 3SEC Arthur F. RyanDirector Sell Plan 117,702 held (−0%) $771.32 $771 +20.9% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 2017,703 held (−0%) $789.28 $16K +18.2% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 2017,723 held (−0%) $788.96 $16K +18.2% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 1117,752 held (−0%) $785.48 $9K +18.7% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 1017,772 held (−0%) $783.62 $8K +19.0% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 917,763 held (−0%) $784.48 $7K +18.9% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 717,745 held (−0%) $786.61 $6K +18.6% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 717,796 held (−0%) $777.46 $5K +19.9% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 517,789 held (−0%) $779.69 $4K +19.6% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 317,786 held (−0%) $780.69 $2K +19.5% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 217,743 held (−0%) $787.34 $2K +18.4% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 217,782 held (−0%) $782.62 $2K +19.2% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 217,784 held (−0%) $781.21 $2K +19.4% —
Mar 3SEC Arthur F. RyanDirector Sell Plan 217,794 held (−0%) $778.30 $2K +19.8% —
Feb 23SEC Huda Y. ZoghbiDirector Sell Plan 3312,650 held (−11%) $780.45 $258K +19.5% —
Feb 23SEC Huda Y. ZoghbiDirector Sell Plan 2982,143 held (−12%) $782.10 $233K +19.2% —
Feb 23SEC Huda Y. ZoghbiDirector Sell Plan 2201,923 held (−10%) $783.29 $172K +19.1% —
Feb 23SEC Huda Y. ZoghbiDirector Sell Plan 2092,441 held (−8%) $781.28 $163K +19.4% —
Feb 23SEC Huda Y. ZoghbiDirector Sell Plan 2082,981 held (−7%) $779.55 $162K +19.6% —
Feb 23SEC Huda Y. ZoghbiDirector Sell Plan 1601,763 held (−8%) $784.45 $126K +18.9% —
Feb 23SEC Huda Y. ZoghbiDirector Sell Plan 561,707 held (−3%) $785.61 $44K +18.7% —
Feb 23SEC Huda Y. ZoghbiDirector Sell Plan 533,189 held (−2%) $778.47 $41K +19.8% —
Feb 23SEC Huda Y. ZoghbiDirector Sell Plan 503,242 held (−2%) $775.50 $39K +20.2% —
Feb 23SEC Huda Y. ZoghbiDirector Sell Plan 493,292 held (−1%) $774.68 $38K +20.4% —
Feb 23SEC Huda Y. ZoghbiDirector Sell Plan 41,703 held (−0%) $790.00 $3K +18.0% —
Feb 11SEC Jason PitofskySvp Controller Sell Plan 5634,813 held (−10%) $778.35 $438K +19.8% —
Feb 11SEC Jason PitofskySvp Controller Sell Plan 5215,767 held (−8%) $776.43 $405K +20.1% —
Feb 11SEC Jason PitofskySvp Controller Sell Plan 3915,376 held (−7%) $777.51 $304K +19.9% —
Feb 11SEC Jason PitofskySvp Controller Sell Plan 2054,608 held (−4%) $779.56 $160K +19.6% —
Feb 11SEC Jason PitofskySvp Controller Sell Plan 1444,326 held (−3%) $783.23 $113K +19.1% —
Feb 11SEC Jason PitofskySvp Controller Sell Plan 754,533 held (−2%) $780.06 $59K +19.5% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 5717,835 held (−0%) $777.56 $44K +19.9% —
Feb 11SEC Jason PitofskySvp Controller Sell Plan 534,272 held (−1%) $785.72 $42K +18.7% —
Feb 11SEC Jason PitofskySvp Controller Sell Plan 374,470 held (−1%) $782.67 $29K +19.1% —
Feb 11SEC Jason PitofskySvp Controller Sell Plan 264,507 held (−1%) $781.37 $20K +19.3% —
Feb 11SEC Jason PitofskySvp Controller Sell Plan 206,288 held (−0%) $775.95 $16K +20.2% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 1217,823 held (−0%) $778.53 $9K +19.8% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 1017,892 held (−0%) $776.59 $8K +20.1% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 517,812 held (−0%) $781.48 $4K +19.3% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 517,818 held (−0%) $779.41 $4K +19.6% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 317,808 held (−0%) $783.34 $2K +19.0% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 217,804 held (−0%) $786.29 $2K +18.6% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 117,803 held (−0%) $787.82 $788 +18.4% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 117,806 held (−0%) $785.71 $786 +18.7% —
Feb 11SEC Jason PitofskySvp Controller Sell Plan 14,325 held (−0%) $784.66 $785 +18.8% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 117,807 held (−0%) $784.59 $785 +18.9% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 117,811 held (−0%) $782.53 $783 +19.2% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 117,817 held (−0%) $780.09 $780 +19.5% —
Feb 11SEC Arthur F. RyanDirector Sell Plan 117,902 held (−0%) $775.63 $776 +20.2% —
Jan 8SEC Bonnie L. BasslerDirector Sell Plan 1,5001,703 held (−47%) $800.00 $1.2M +16.6% —
Nov 24SEC Bonnie L. BasslerDirector Sell Plan 7601,548 held (−33%) $750.00 $570K +24.3% —
Nov 10SEC Jason PitofskyVp Controller Sell 4314,233 held (−9%) $651.43 $281K +43.2% —
Oct 31SEC Christine A. PoonDirector Sell 2,7355,467 held (−33%) $653.50 $1.8M +42.7% —
Oct 31SEC Christine A. PoonDirector Sell 1,9153,552 held (−35%) $654.42 $1.3M +42.5% —
Oct 31SEC Christine A. PoonDirector Sell 7122,740 held (−21%) $656.50 $467K +42.0% —
Oct 31SEC Christine A. PoonDirector Sell 6508,202 held (−7%) $652.68 $424K +42.9% —
Oct 31SEC Christine A. PoonDirector Sell 3882,352 held (−14%) $657.29 $255K +41.9% —
Oct 31SEC Christine A. PoonDirector Sell 1003,452 held (−3%) $655.10 $66K +42.4% —
Historical context

Similar past setups: not applicable. REGN has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with REGN in the Research Lab

REGN has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

REGN closeInsider buyInsider sale
4006008001,000DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-01-12EEarnings release filed 2026-01-30EEarnings release filed 2026-04-08EEarnings release filed 2026-04-29EEarnings release filed 2026-07-06EEarnings release filed 2026-07-30EEarnings release filed 2026-10-06Sold $70,524 on 2026-05-01 · Arthur F. RyanSold $77,727 on 2026-04-01 · Arthur F. RyanSold $78,550 on 2026-03-02 · Arthur F. RyanSold $130,030 on 2026-07-02 · Arthur F. RyanSold $570,000 on 2025-11-20 · Bonnie L. BasslerSold $960,000 on 2026-08-10 · Huda Y. Zoghbi, Kathryn GuariniSold $969,708 on 2026-09-03 · Marion McCourtSold $1,200,000 on 2026-01-07 · Bonnie L. BasslerSold $1,279,812 on 2026-02-19 · Huda Y. ZoghbiSold $1,372,750 on 2026-09-02 · Kathryn Guarini, Marion McCourtSold $1,503,764 on 2026-11-16 · George L. Sing, Marion McCourtSold $1,662,911 on 2026-02-09 · Arthur F. Ryan, Jason PitofskySold $3,032,070 on 2026-10-30 · Kathryn Guarini, Marion McCourt, Michael S. BrownSold $3,204,376 on 2026-10-14 · Andrew J. MurphySold $3,827,159 on 2026-11-04 · Jason PitofskySold $5,757,021 on 2026-11-17 · Andrew J. Murphy, George L. SingSold $7,219,274 on 2026-11-03 · Huda Y. ZoghbiSold $32,276,206 on 2026-11-02 · Christine A. Poon, George L. Sing, Joseph J. Larosa
Bought, 12 months$0
Sold, 12 months$65.2M
Insiders buying0
Insiders selling11

Regeneron Pharmaceuticals insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 11 sold $65.2M of REGN stock on the open market; P/E 21.0 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

REGN insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $5.1M sold (8 trades)Q4 2025Q1 2026: $4.2M sold (49 trades)Q1 2026Q2 2026: $148K sold (21 trades)Q2 2026Q3 2026: $3.4M sold (6 trades)Q3 2026Q4 2026: $56.8M sold (90 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$56.8M90
Q3 2026—0$3.4M6
Q2 2026—0$148K21
Q1 2026—0$4.2M49
Q4 2025—0$5.1M8

Valuation, profit and volume

P/E (trailing)21.0Sector median 25.0
Market value$98.34BBiotechnology
Profit margin28.5%Revenue growth +36.3%
Volume vs. 50-day0.9×Last 5 sessions

Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Regeneron Pharmaceuticals insiders reported open-market purchases totaling $0, while 11 insiders reported sales totaling $65.2M. 136 of 174 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

REGN earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 6, 2026 -7.4% None +2.2%S&P +0.3% +21.9%
Jul 30, 2026 +6.0% Sold $130K +9.7%S&P +2.4% +4.3%
Jul 6, 2026 +7.6% Sold $130K +3.4%S&P +0.4% +14.2%
Apr 29, 2026 -2.0% Sold $78K -3.4%S&P +1.0% -12.9%
Apr 8, 2026 +3.2% Sold $78K +1.0%S&P +3.1% -6.9%
Jan 30, 2026 -0.6% Sold $1.2M +0.7%S&P +0.2% +4.4%
Jan 12, 2026 +1.6% Sold $1.2M -4.7%S&P -0.0% +3.3%
Oct 28, 2025 +3.7% None +11.5%S&P +0.3% +19.6%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

REGN short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 57% of volume sold short2026-08-27: 43% of volume sold short2026-08-28: 59% of volume sold short2026-08-31: 61% of volume sold short2026-09-01: 61% of volume sold short2026-09-02: 66% of volume sold short2026-09-03: 65% of volume sold short2026-09-04: 60% of volume sold short2026-09-08: 65% of volume sold short2026-09-09: 52% of volume sold short2026-09-10: 50% of volume sold short2026-09-11: 47% of volume sold short2026-09-14: 50% of volume sold short2026-09-15: 46% of volume sold short2026-09-16: 55% of volume sold short2026-09-17: 67% of volume sold short2026-09-18: 64% of volume sold short2026-09-21: 58% of volume sold short2026-09-22: 44% of volume sold short2026-09-23: 44% of volume sold short2026-09-24: 46% of volume sold short2026-09-25: 43% of volume sold short2026-09-28: 42% of volume sold short2026-09-29: 51% of volume sold short2026-09-30: 44% of volume sold short2026-10-01: 43% of volume sold short2026-10-02: 52% of volume sold short2026-10-05: 52% of volume sold short2026-10-06: 45% of volume sold short2026-10-07: 45% of volume sold short2026-10-08: 47% of volume sold short2026-10-09: 47% of volume sold short2026-10-12: 39% of volume sold short2026-10-13: 42% of volume sold short2026-10-14: 48% of volume sold short2026-10-15: 50% of volume sold short2026-10-16: 41% of volume sold short2026-10-19: 57% of volume sold short2026-10-20: 61% of volume sold short2026-10-21: 59% of volume sold short2026-10-22: 58% of volume sold short2026-10-23: 44% of volume sold short2026-10-26: 39% of volume sold short2026-10-27: 40% of volume sold short2026-10-28: 57% of volume sold short2026-10-29: 59% of volume sold short2026-10-30: 49% of volume sold short2026-11-02: 55% of volume sold short2026-11-03: 53% of volume sold short2026-11-04: 27% of volume sold short2026-11-05: 38% of volume sold short2026-11-06: 34% of volume sold short2026-11-09: 39% of volume sold short2026-11-10: 37% of volume sold short2026-11-11: 54% of volume sold short2026-11-12: 48% of volume sold short2026-11-13: 42% of volume sold short2026-11-16: 35% of volume sold short2026-11-17: 50% of volume sold short2026-11-18: 46% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 46%20-day average: 46%Prior 2 months: 51%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded REGN

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 27, 2026Jul 21, 2026 +26.7%

Insiders at Regeneron Pharmaceuticals

InsiderBoughtSoldLast filingPast buys beat S&PScore
George L. SingDirector — $22.3M Nov 18, 2026 — —
Christine A. PoonDirector — $11.8M Nov 4, 2026 — —
Huda Y. ZoghbiDirector — $9.1M Nov 5, 2026 — —
Andrew J. MurphyCo-Chief Scientific Officer — $8.0M Nov 18, 2026 — —
Jason PitofskySvp Controller — $5.7M Nov 6, 2026 — —
Joseph J. LarosaGeneral Counsel — $4.3M Nov 4, 2026 — —
Marion McCourtEvp Commercial — $3.5M Nov 18, 2026 — —
Bonnie L. BasslerDirector — $1.8M Jan 8, 2026 — —
Michael S. BrownDirector — $1.7M Nov 3, 2026 — —
Kathryn GuariniDirector — $1.0M Nov 3, 2026 — —
Arthur F. RyanDirector — $435K Jul 7, 2026 — —
Christopher R. FenimoreCFO — — Nov 4, 2026 — —
N. Anthony ColesDirector — — Jan 6, 2026 — —
Joseph L. GoldsteinDirector — — Jan 6, 2026 — —
Craig B. ThompsonDirector — — Jan 6, 2026 — —
David P. SchenkeinDirector — — Jan 6, 2026 — —
Leonard S. SchleiferCEO, President — — Jan 5, 2026 — —
George YancopoulosPresident, Chair — — Jan 5, 2026 — —
Plew Daniel P. VanEvp & General Mgr, Industrial — — Dec 11, 2025 — —

Board links: companies that share insiders with REGN

Directors and executives who filed Form 4s for REGN and another company in the last 12 months.

See the map →
  • CRLCharles River Laboratories Craig B. Thompson Director here · Director at CRL · latest filing May 12, 2026
  • PRUPrudential Financial Christine A. Poon Director here · Director at PRU · latest filing Nov 4, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

REGN stock: common questions

Are Regeneron Pharmaceuticals insiders buying REGN stock?

No. No Regeneron Pharmaceuticals insider reported an open-market purchase of REGN in the past 12 months.

Are Regeneron Pharmaceuticals insiders selling REGN stock?

11 insiders reported sales worth $65.2M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is REGN's P/E ratio?

REGN trades at about 21.0 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is REGN's 52-week range?

Over the past year REGN has traded between $599.96 and $973.36. It last closed at $932.53 on Nov 19, 2026.